Cancerwise Blog | UT MD Anderson
The 1.2‑inch tumor in my lower left lung was found by chance during a routine physical.
In August 2026, a lung cancer patient describes how a rare NTRK1 fusion identified through genetic testing qualified him for a Phase 2 targeted‑therapy clinical trial of TL‑118 at UT MD Anderson, outlining the decision‑making process, expectations, and early outcomes.
This case highlights the importance of molecular profiling in advanced lung cancer to identify rare actionable mutations, enables enrollment in precision‑medicine trials even for uncommon alterations, and demonstrates that early-phase studies can rapidly translate into clinical benefit for patients with otherwise limited treatment options.
Evidence level: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT